Key statistics dashboard for Adicet Bio, Inc. (ACET). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Adicet Bio, Inc. is a biotechnology firm dedicated to pioneering allogeneic gamma delta T cell therapies, aiming to treat cancer and various other diseases. The company’s strategy involves engineering gamma delta T cells with chimeric antigen receptors (CARs) and T cell receptor-like antibodies.
Stock Data
| Price | $9.05 |
| Market Cap | $85M |
| Beta | 1.58 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.79 |
| Price / Book | 0.81 |
| P/S | 0.00 |
| P/FCF | -1.00 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 6.71 |
| Quick Ratio | 6.71 |
| Cash Ratio | 1.84 |
| Debt / Equity | 0.11 |
| Debt / Assets | 8.68% |
| Interest Coverage | -1280.36 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -4.65 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 11.18 |
| Cash per share | 11.00 |
| FCF per share | -7.91 |
| Tangible Book Value per share | 11.18 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 12 |
| Avg rating (1-5) | 0.75 |
Related companies: ACRV · ADAG · CRVO · GANX · HOWL · IMUX · IOBT
Explore sector: Healthcare · Biotechnology
More sections of ACET: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks